S-Adenosyl-L-Methionine (SAMe) in Liver Disease

Introduction to SAMe Therapy

The European Association for the Study of the Liver explicitly states that no specific pharmacological therapy for alcoholic cirrhosis, including SAMe, has demonstrated unequivocal efficacy, with no change in liver fibrosis when assessed by histology 5
The American Association for the Study of Liver Diseases noted that despite strong theoretical rationale and supportive individual trials, a Cochrane review of 9 randomized controlled trials with 434 patients in different stages of alcoholic liver disease did not demonstrate any significant benefit of SAMe on total mortality, liver-related mortality, complications, or liver transplantation 1

The Korean Association for the Study of the Liver reviewed the evidence and concluded that while one clinical study found SAMe improved survival in Child-Pugh class A and B patients, a subsequent meta-analysis found no statistically significant effects on overall mortality, liver-related mortality, complications, or liver transplantation results 2, 3, 4
The American Association for the Study of Liver Diseases recommends prioritizing alcohol abstinence as the major therapeutic goal, as it has the strongest evidence for mortality reduction, and not prescribing SAMe as primary therapy due to insufficient evidence 1, 6

SAMe functions as a methyl donor in biochemical reactions and serves as a precursor to glutathione, the primary intracellular antioxidant, but its use in alcoholic liver disease has not demonstrated significant benefits 2, 3, 4
SAMe demonstrates favorable tolerability with primarily mild, transient gastrointestinal complaints as the most common adverse events, but its use should be approached with caution due to lack of proven benefit 6